Atlas Healthcare Fund by VST Capital Entered Eli Lilly at $350 in 2020 — The Stock Now Trades Above $1,200
New York, United States, July 15th, 2026, FinanceWire
Atlas Healthcare Fund managed by VST Capital, today highlighted a series of early conviction investment decisions that have defined its track record since launch — none more striking than its position in Eli Lilly and Company, entered at approximately $350 per share in 2020, years before GLP-1 receptor agonists became the most consequential pharmaceutical story of the decade. Eli Lilly now trades above $1,200, a gain of more than 246% from the fund’s entry point.
At the time of purchase, Lilly’s tirzepatide was in Phase II trials with limited analyst coverage and minimal institutional positioning. VST Capital’s investment team had read the data, understood the mechanism, and build the position quietly. The market caught up years later....
